Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Chart of the Day: What’s next for the US stock market? (16.09.2026)
Market Wrap: The Market Slows Its Declines Ahead of the Fed
Economic Calendar: Time for an interest rate hike? (16.09.2026)
Morning Wrap: Market seeks balance ahead of Fed decision (16.09.2026)